Review Article

Pharmacotherapy for Alcohol Dependence

The Why, the What and the Wherefore

E. T. Goh; M. Y. Morgan

Disclosures

Aliment Pharmacol Ther. 2017;45(7):865-882. 

In This Article

Abstract and Introduction

Abstract

Background The development of alcohol dependence is associated with significant morbidity and mortality. For the majority of affected people the most appropriate goal, in terms of drinking behaviour, is abstinence from alcohol. Psychosocial intervention is the mainstay of the treatment but adjuvant pharmacotherapy is also available and its use recommended.

Aim To provide an updated analysis of current and potential pharmacotherapeutic options for the management of alcohol dependence. In addition, factors predictive of therapeutic outcome, including compliance and pharmacogenetics, and the current barriers to treatment, including doctors' unwillingness to prescribe these agents, will be explored.

Methods Relevant papers were selected for review following extensive, language- and date-unrestricted, electronic and manual searches of the literature.

Results Acamprosate and naltrexone have a substantial evidence base for overall efficacy, safety and cost-effectiveness while the risks associated with the use of disulfiram are well-known and can be minimised with appropriate patient selection and supervision. Acamprosate can be used safely in patients with liver disease and in those with comorbid mental health issues and co-occurring drug-related problems. A number of other agents are being investigated for potential use for this indication including: baclofen, topiramate and metadoxine.

Conclusion Pharmacotherapy for alcohol dependence has been shown to be moderately efficacious with few safety concerns, but it is substantially underutilised. Concerted efforts must be made to remove the barriers to treatment in order to optimise the management of people with this condition.

Comments

3090D553-9492-4563-8681-AD288FA52ACE

processing....